Butyrophilin-Like Protein 2 (BTNL2) Antibody
357.5€ (100 µg)
Por favor contáctenos para obtener información detallada sobre el precio y disponibilidad.
935106861
info@markelab.com
name
Butyrophilin-Like Protein 2 (BTNL2) Antibody
category
Primary Antibodies
provider
Abbexa
reference
abx122175
tested applications
ELISA, WB, IHC
Description
Rabbit Polyclonal against the BTNL2 protein.
Documents del producto
Instrucciones
Data sheet
Product specifications
| Category | Primary Antibodies |
| Immunogen Target | Target: Butyrophilin-Like Protein 2 (BTNL2) Immunogen: Recombinant fragment corresponding to 54-245 AA of human BTNL2. |
| Host | Rabbit |
| Reactivity | Human |
| Assay Type | Concentration: Lyophilized form: Not applicable. After reconstitution: 1 mg/ml. |
| Recommended Dilution | ELISA: 1/20000 - 1/80000, WB: 1/500 - 1/2000, IHC: 1/100 - 1/200. Optimal dilutions/concentrations should be determined by the end user. |
| Clonality | Polyclonal |
| Conjugation | Unconjugated |
| Isotype | IgG |
| Purification | Purified by antigen affinity column chromatography. |
| Size 1 | 100 µg |
| Size 2 | 1 mg |
| Form | Lyophilized |
| Tested Applications | ELISA, WB, IHC |
| Buffer | Prior to lyophilization: 1% BSA and 0.02% NaN3. |
| Availability | Shipped within 7-15 working days. |
| Storage | Store at -20 °C. Avoid repeated freeze/thaw cycles. |
| Dry Ice | No |
| NCBI Accession | BC127642 |
| Alias | SS2,BTN7,BTL-II,HSBLMHC1,Butyrophilin-like protein 2 |
| Background | Antibody anti-BTNL2 |
| Status | RUO |
| Note | THIS PRODUCT IS FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC, THERAPEUTIC OR COSMETIC PROCEDURES. NOT FOR HUMAN OR ANIMAL CONSUMPTION. |
Descripción
Butyrophilin like 2 (BTNL2) is an immunomodulatory protein expressed in epithelial and lymphoid tissues. BTNL2 interacts with T cells, modulating their activation and proliferation, thus playing a key role in maintaining immune homeostasis and preventing excessive immune responses. Genetic polymorphisms in BTNL2 are linked to susceptibility to autoimmune diseases, including sarcoidosis, rheumatoid arthritis, and Crohn's disease, as well as some cancers. Its expression in mucosal tissues suggests a role in regulating local immune responses to pathogens and maintaining the epithelial barrier. BTNL2's therapeutic potential is under investigation, particularly its ability to influence immune tolerance and suppress aberrant immune activation in inflammatory diseases and transplant rejection.
